Lithium Ion

Lithium Ion

SCHEMBL549062

[HH].[Li+].[OH-]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL28269112 0.82 CYP3A4 (0.33)
Lithium Ion SCHEMBL28411406 0.82
Lithium Ion SCHEMBL26656220 0.82
Lithium Ion SCHEMBL8675018 0.82 CYP3A4 (0.33)
Lithium Ion SCHEMBL1890966 0.82
Lithium Ion SCHEMBL1714 0.82
Lithium Ion SCHEMBL9399655 0.67
Lithium Ion SCHEMBL2464515 0.67
Lithium Ion SCHEMBL1929287 0.67
Iodide SCHEMBL6017508 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735452-A2 HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN Merck Patent GmbH (DE) 2026-05-06 EP disclosed
US-20260116868-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-04-30 US disclosed
EP-4732837-A2 NOVEL PRMT5 INHIBITORS Amgen Inc. (US) 2026-04-29 EP disclosed
EP-4263545-B1 PRMT5 INHIBITORS AMGEN INC (US) 2026-04-01 EP disclosed
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2026-02-12 US disclosed
US-12521393-B2 Cytotoxicity targeting chimeras for CCR2-expressing cells GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-13 US disclosed
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 US disclosed
EP-4640280-A2 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-10-29 EP disclosed
EP-4634162-A1 BENZIMIDAZOLE DERIVATIVES Syngenta Crop Protection AG (CH) 2025-10-22 EP disclosed
EP-4384223-B1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-10-01 EP disclosed
US-5552397-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1996-09-03 US disclosed
US-5461025-A Herbicides KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 1995-10-24 US disclosed
US-5354766-A 2-Ethoxy-1-((2'(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl)methyl)benzimidazole-7-carboxylic acid; hypotensive agents; CNS activity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-10-11 US disclosed
EP-0599444-A1 Dual action inhibitors E.R. SQUIBB &amp; SONS, INC. (US) 1994-06-01 EP disclosed
EP-0575378-A1 BENZENESULFONYLUREA DERIVATIVES KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 1993-12-29 EP disclosed
US-5243054-A Hypotensive agents, cardiovascular disorders or nervous system disorders TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-09-07 US disclosed
EP-0520423-A2 Heterocyclic compounds, their production and use as angiotensin II antagonists TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-12-30 EP disclosed
WO-1992015568-A1 BENZENESULFONYLUREA DERIVATIVES KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 1992-09-17 WO disclosed
US-4810300-A HEAT RESISTANT MARKING INKS AND PROTECTIVE COATINGS ZYP COATINGS, INC. (US) 1989-03-07 US disclosed
US-4741775-A BAR CODES ZYP COATINGS, INC. (US) 1988-05-03 US disclosed